We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Airway Microbiome Altered in Severe Asthma Linked to Neutrophils

By LabMedica International staff writers
Posted on 06 Jun 2019
Patients with mild-to-moderate asthma can experience difficulty breathing and it is especially difficult for those with Severe Asthma where symptoms can be life threatening. More...
In either case, patients cannot participate in daily activities if their disease is uncontrolled.

As there is no single ‘gold standard’ test, clinical asthma diagnosis is based on evidence of recurrent respiratory symptoms; reversibility with anti-asthma treatment; and variable airflow obstruction. Demonstrating any or all three, of these features in a clinical setting is challenging as the disease fluctuates.

A team of scientists working with the Global Medical Franchise GSK (Brentford, UK) utilized sputum metagenomic profiling to determine if there was a relationship between neutrophilic inflammation and the airway microbiome in severe asthma. No previous metagenomic analysis has been undertaken in severe asthma to understand this relationship. Induced sputum was obtained from four cohorts as part of the U-BIOPRED study programme: (A) 97 severe asthma, non-smokers, (B) 50 severe asthma, ex/current smokers, (C) 25 steroid treated non-severe asthma and (D) 23 healthy controls.

Samples were prepared for sequencing with the Illumina Nextera kit and quantified with Quant-iT dsDNA High Sensitivity assays. Libraries were pooled and run with 100 bp paired-end sequencing protocols on the Illumina HiSeq 2500 platform., Taxonomic profiling (MetaPhlAn2), reads mapped to KEGG v75.0 (Diamond), accepting hits ≥20 amino acids with ≥80% similarity and pathway counts derived from summing the relative abundance of KOs to the pathway(s) they belong to.

The scientists reported that there were reductions in the richness and diversity between severe asthmatics and the two control cohorts. On analysis of the metagenomic profiles, taxa alpha diversity inversely correlated with sputum neutrophil percent. Veillonellaceae, Prevotellaceae, Neisseriaceae, Streptococcaceae, Porphyromonadaceae, and Micrococcaceae were all negatively correlated with percent neutrophils. Moraxellaceae was positively correlated with percent neutrophils. The team reported 67 Operational Taxonomic units (OTUs) were significantly correlated with percent neutrophils, and 65 OTUs were negatively correlated with percent neutrophils. Two OTUs: Moraxella catarrhalis and Haemophilus influenzae, were positively correlated. Thirty genes were negatively correlated with percent neutrophils. There was no correlation with sputum eosinophils.

The authors that their study associates an abnormal airway metagenomic profile in severe asthma with neutrophilic airway inflammation. Further focus is needed to better understand the dynamics of this relationship, as severe neutrophilic asthma remains an important clinically unmet need. The study was presented on May 22, 2019, at the American Thoracic Society Annual Meeting, held May 17-22, 2019, in Dallas, Texas, USA.

Related Links:
Global Medical Franchise GSK


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.